Abpro Holdings Receives FDA IND Clearance for Lead Oncology Candidate ABP-102 / CT-P72
Summary
Abpro Holdings announced FDA Investigational New Drug (IND) clearance for its lead multispecific antibody oncology program, ABP-102 / CT-P72, enabling the initiation of a Phase 1 clinical trial.
Key Events
-
FDA IND Clearance for Lead Oncology Program
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro's lead multispecific antibody oncology program, co-developed with Celltrion, Inc.
-
Initiation of Phase 1 Clinical Trial
This clearance enables the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 / CT-P72 in patients with HER2-positive solid tumors, anticipated in the first half of 2026.
-
Strategic Co-Development with Celltrion
The Phase 1 clinical study will be led by co-development partner Celltrion, Inc., underscoring the ongoing joint strategic collaboration for the program's robust progression.
-
Differentiated Therapeutic Design
ABP-102 / CT-P72 is a multispecific HER2 x CD3 T-cell engager engineered for enhanced tumor selectivity and optimized CD3 binding, aiming to minimize damage to healthy tissue and reduce the risk of cytokine release syndrome.
Analysis
The FDA Investigational New Drug (IND) clearance for ABP-102 / CT-P72 is a significant milestone for Abpro Holdings, as it transitions their lead multispecific antibody oncology program from preclinical to clinical development. For a biotechnology company, advancing a drug candidate into Phase 1 trials is a critical de-risking event that validates the preclinical work and opens the path for potential future commercialization. The co-development with Celltrion, Inc. further strengthens the program's credibility and resource backing. This development could attract increased investor attention, given the high unmet medical need in HER2-positive solid tumors and the differentiated design of ABP-102 / CT-P72 aimed at improving safety and efficacy.
At the time of this filing, ABP was trading at $4.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11M. The 52-week trading range was $3.78 to $54.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.